Reducing Activities: company scaling back some business operations while continuing others
Stay Scaling Back
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. On February 5, 2020, the company announced management changes effective from April 1, 2020.
Reducing Activities: company scaling back some business operations while continuing others
Stay Scaling BackSuspended new clinical trials in Russia. Astellas halts antibiotics production in Russia. In a significant development, Astellas, a leading Japanese pharmaceutical company, has decided to halt the production of its antibiotics, Vilprafen and Vilprafen Solutab (Josamycin), in Russia. This decision has instigated a scarcity of these drugs within Russian pharmacies, with virtually no supplies available in Moscow. 24.02.2022: One of the two legal entities (ASTELLAS PHARMA JSC) was liquidated. Astellas had/has a legal presence in Russia, engaged in certain activities (production, sale of drugs). However, after the start of the full-scale Russian invasion of Ukraine, it suspended the production of certain drugs in Russia and transferred the rights to some products to another entity.